On June 1, 2021, Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, announced the closing of its initial public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,500,000 additional shares of common stock, at a public offering price of $16.00 per share. All of the shares were offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, were $184 million. The shares began trading on the Nasdaq Global Select Market on May 27 under the ticker symbol “DAWN.”

The Wilson Sonsini team that advised Day One on IP matters related to the transaction includes Maya Skubatch, Julia Minitti, and Ying Chen.

For more information, please see Day One’s press release.